Last reviewed · How we verify
KNO3, potassium nitrate
KNO3, potassium nitrate is a Small molecule drug developed by Washington University School of Medicine. It is currently in Phase 1 development. Also known as: saltpeter.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | KNO3, potassium nitrate |
|---|---|
| Also known as | saltpeter |
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- TRAUMATIC ULCER
- Lightheadedness
- ANGULAR CHEILITIS
- GINGIVAL PAIN
- GINGIVAL SWELLING
- LIP ULCERATION
- HEADACHE
- PYREXIA
- SEASONAL ALLERGY
- Anxiety worsening
- Bell's palsy
- Back Pain, Worsening
Key clinical trials
- A Clinical Study to Assess an Experimental Dentifrice in an Experimental Model of Early Stage Caries (NA)
- SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial (PHASE2)
- Matching Perfusion and Metabolic Activity in HFpEF (PHASE2)
- Inorganic NItrate and EXercise Performance in Heart Failure (iNIX-HF): Dose Response (PHASE1, PHASE2)
- An Erosion Study to Investigate the Efficacy of an Experimental Dentifrice to Remineralize Enamel (NA)
- The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF) (PHASE2)
- Clinical and Radiographic Evaluation of Potassium Nitrate in Polycarboxylate Versus Mineral Trioxide Aggregate in Vital Pulpotomy in Primary Molars (NA)
- The Impact of Inorganic Nitrate-rich Beetroot Juice on Microvascular Blood Flow and Cognitive Function (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KNO3, potassium nitrate CI brief — competitive landscape report
- KNO3, potassium nitrate updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI
Frequently asked questions about KNO3, potassium nitrate
What is KNO3, potassium nitrate?
Who makes KNO3, potassium nitrate?
Is KNO3, potassium nitrate also known as anything else?
What development phase is KNO3, potassium nitrate in?
What are the side effects of KNO3, potassium nitrate?
Related
- Manufacturer: Washington University School of Medicine — full pipeline
- Also known as: saltpeter
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing